Evaluating the Effect of a Shared Care Pathway Intervention on Unplanned Presentations to Hospital by Chemotherapy Outpatients

Not Applicable

Completed

• Conditions: Cancer; Chemotherapy related unplanned hospital presentations; Chemotherapy related symptoms; Cancer - Any cancer

• Registration Number: ACTRN12614001113640
• Lead Sponsor: The University of Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-10-21
• Study Completion: 2019-02-12
• Last Update Posted: 8 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 353

Inclusion Criteria

1) Over 18 years of age;
2) Commencing their first cycle of chemotherapy as an outpatient at one of the participating cancer centres;
3) Fully aware of their cancer diagnosis;
4) Residing at one of the suburbs serviced by the community centres enrolled in the study, for the duration of the study.

Exclusion Criteria

1) Unable to give informed consent;
2) Receiving treatment for haematological cancers;
3) Receiving concurrent chemotherapy and radiotherapy.
4) Non English Speaking

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
nplanned hospital presentations as assessed by data linkage to medical records[A the end of the third cycle (week 9, but this can vary depending on chemotherapy regimen used)]

Secondary Outcome Measures

Name	Time	Method
Anxiety and depression assessed using HADS tool[Measured at baseline and end of cycles 1 to 3 (week 3, 6 and 9, but this can vary depending on chemotherapy regimen used)];The EORTC QLQ-C30 will be used to assess cancer-specific function and symptoms and global quality of life [Measured at baseline and end of cycles 1 to 3 (week 3, 6 and 9, but this can vary depending on chemotherapy regimen used)];The CBI-B will be used to assess self-efficacy and confidence for coping with cancer and quality of life[Measured at baseline and end of cycles 1 to 3 (week 3, 6 and 9, but this can vary depending on chemotherapy regimen used)];Quality of life assessed using the SF-36[Measured at baseline and end of cycles 1 to 3 (week 3, 6 and 9, but this can vary depending on chemotherapy regimen used)]